Sandbox g55: Difference between revisions
Jump to navigation
Jump to search
Gerald Chi- (talk | contribs) mNo edit summary |
Gerald Chi- (talk | contribs) mNo edit summary |
||
Line 9: | Line 9: | ||
::::* 1.2.1 '''Susceptible to all tested drugs''' | ::::* 1.2.1 '''Susceptible to all tested drugs''' | ||
:::::* Preferred regimen: [[Piperacillin-Tazobactam]] 3.375 mg IV q6h | :::::* Preferred regimen: [[Piperacillin-Tazobactam]] 3.375 mg IV q6h | ||
:::::* Alternative regimen (1): [[Ciprofloxacin]] 400 mg IV q12h | :::::* Alternative regimen (1): [[Ciprofloxacin]] 400 mg IV q12h | ||
:::::* Alternative regimen (2): [[Cefepime]] 2 gm IV q8h | :::::* Alternative regimen (2): [[Cefepime]] 2 gm IV q8h | ||
Revision as of 03:28, 22 July 2015
- Enterobacter
Return to Top
- Enterobacter species including E. aerogenes and E. cloacae
- 1. Non–life-threatening infections or MDR-GNB prevalence < 20%
- 1.1 Empiric antimicrobial therapy pending in vitro susceptibility
- Preferred regimen: Piperacillin-Tazobactam 3.375 mg IV q6h
- Alternative regimen: Ciprofloxacin 400 mg IV q12h
- 1.2 In vitro susceptibility available
- 1.2.1 Susceptible to all tested drugs
- Preferred regimen: Piperacillin-Tazobactam 3.375 mg IV q6h
- Alternative regimen (1): Ciprofloxacin 400 mg IV q12h
- Alternative regimen (2): Cefepime 2 gm IV q8h
- Acanthamoeba
Return to Top
- Acanthamoeba species
- Balamuthia mandrillaris
Return to Top
- Balamuthia mandrillaris